Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 4/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3575584 | 0.92 | PARP15 (0.53) | PARP15PARP10PARP2SIGMAR1TDP1 | |
| SCHEMBL3989257 | 0.92 | PARP15 (0.53) | PARP15PARP10PARP2SIGMAR1TDP1 | |
| SCHEMBL1987414 | 0.90 | PARP10 (0.54) | PARP15PARP10PARP2 | |
| SCHEMBL9815659 | 0.88 | PARP15 (0.41) | PARP15PARP10PARP2SIGMAR1TDP1 | |
| SCHEMBL9815661 | 0.88 | PARP15 (0.41) | PARP15PARP10PARP2SIGMAR1TDP1 | |
| SCHEMBL3166948 | 0.87 | DHFR (0.42) | PARP15PARP10PARP2SIGMAR1TDP1 | |
| SCHEMBL5659072 | 0.87 | TDP1 (0.63) | TDP1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5657330 | 0.84 | CARM1 (0.48) | SIGMAR1 | |
| SCHEMBL29024848 | 0.84 | PARP15 (0.64) | PARP15PARP10PARP2SIGMAR1TDP1 | |
| SCHEMBL9815670 | 0.83 | PARP15 (0.39) | PARP15PARP10PARP2SIGMAR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731954-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RES INC (US) | 2023-08-22 | — | — | US | claimed |
| EP-3740493-B1 | INHIBTEURS DE L'INDOLEAMINE 2,3-DIOXYGÉNASE ET/OU DU TRYPTOPHANE DIOXYGÉNASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-01 | — | — | EP | claimed |
| CN-105980386-B | Pyrazolo compounds and uses thereof | 基因泰克公司 | 2021-08-13 | — | — | CN | claimed |
| US-20210238161-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-08-05 | — | — | US | claimed |
| US-11001568-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-05-11 | — | — | US | claimed |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-31 | — | — | US | claimed |
| EP-3740493-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | Idorsia Pharmaceuticals Ltd (CH) | 2020-11-25 | — | — | EP | claimed |
| CN-111601810-A | Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase | 爱杜西亚药品有限公司 | 2020-08-28 | — | — | CN | claimed |
| US-20200157077-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-21 | — | — | US | claimed |
| EP-2970307-B1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-03-11 | — | — | EP | claimed |
| CN-101272774-A | Substituted acrylamide derivative and pharmaceutical composition comprising the same | DAIICHI SANKYO CO LTD (JP) | 2008-09-24 | — | — | CN | claimed |
| EP-1908466-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-04-09 | — | — | EP | claimed |
| EP-1880720-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-01-23 | — | — | EP | claimed |
| EP-0830349-B1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | DU PONT PHARM CO (US) | 2000-03-22 | — | — | EP | claimed |
| US-5877312-A | Method for preparing alkylating agents for their use for alkylating cyclic ureas | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-03-02 | — | — | US | claimed |
| EP-0830349-A1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-25 | — | — | EP | claimed |
| US-5637780-A | Method for preparing alkylating agents and their use for alkylating cyclic ureas | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-06-10 | — | — | US | claimed |
| EP-0767770-A1 | METHOD FOR PREPARING ALKYLATING AGENTS AND THEIR USE FOR ALKYLATING CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-04-16 | — | — | EP | claimed |
| WO-1996039393-A1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-12 | — | — | WO | claimed |
| WO-1996000708-A1 | METHOD FOR PREPARING ALKYLATING AGENTS AND THEIR USE FOR ALKYLATING CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001568-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, BMI1 | PARP15 738/4885PARP10 562/4885PARP2 671/4885 |
| US-11731954-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, BMI1 | PARP15 738/4885PARP10 562/4885PARP2 671/4885 |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDO2, TDO2, IDO1 | PARP15 1597/4885PARP10 1989/4885PARP2 1412/4885 |
| US-20200157077-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, BMI1 | PARP15 738/4885PARP10 562/4885PARP2 671/4885 |
| US-20210238161-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, BMI1 | PARP15 738/4885PARP10 562/4885PARP2 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.